carmustine has been researched along with Renal Insufficiency in 3 studies
Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One patient had a retinal vein thrombosis." | 2.39 | Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support. ( Baars, JW; de Glas-Vos, CW; Rodenhuis, S; Thomas, BL; van der Lelie, H; van Dijk, MA; van Oers, RH; von dem Borne, AE, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (66.67) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Farnault, L | 1 |
| Venton, G | 1 |
| Pourroy, B | 1 |
| Jourde-Chiche, N | 1 |
| Ivanov, V | 1 |
| Arcani, R | 1 |
| Roche, P | 1 |
| Mercier, C | 1 |
| Colle, J | 1 |
| Fanciullino, R | 1 |
| Costello, RT | 1 |
| van der Lelie, H | 1 |
| Baars, JW | 1 |
| Rodenhuis, S | 1 |
| van Dijk, MA | 1 |
| de Glas-Vos, CW | 1 |
| Thomas, BL | 1 |
| van Oers, RH | 1 |
| von dem Borne, AE | 1 |
| Merouani, A | 1 |
| Shpall, EJ | 1 |
| Jones, RB | 1 |
| Archer, PG | 1 |
| Schrier, RW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Prevention Of Nephrotoxicity Following Allogeneic Bone Marrow Transplantation Using Urodilatin (Ularitide,Atrial Natriuretic Peptide) and Mannitol.[NCT00390624] | Phase 2 | 20 participants (Anticipated) | Interventional | 2003-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for carmustine and Renal Insufficiency
| Article | Year |
|---|---|
Hemolytic uremic syndrome after high dose chemotherapy with autologous stem cell support.
Topics: Adult; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; An | 1995 |
1 trial available for carmustine and Renal Insufficiency
| Article | Year |
|---|---|
Renal function in high dose chemotherapy and autologous hematopoietic cell support treatment for breast cancer.
Topics: Adult; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; | 1996 |
1 other study available for carmustine and Renal Insufficiency
| Article | Year |
|---|---|
Severe renal insufficiency is not an absolute pitfall to autologous stem cell transplantation with BeEAM (bendamustine, etoposide, cytarabine, melphalan) conditioning regimen.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Autografts; Carmustine; Cytarabine; Humans; L | 2019 |